Clinical trial NCT00208221 (phase 3, status: terminated)
Conditions: hypertension, type 2 diabetes, albuminuria
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ramipril, ramipril-telmisartan
SMILES: [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Reason stopped: 
    not enough recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female over the age of 18 years

          -  Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg

          -  Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C)
             less than 0.080

          -  UA ratio albumin:creatinine 2.0 to 25 mg/mmol

        Exclusion Criteria:

          -  DBP > 104 mmhg

          -  Woman not surgically sterile or menopausal.

          -  Premenopausal women whoo are not surgically sterile or who are not practicing
             acceptable means of birth control and do not agree to submit to periodic pregnancy
             tests.

          -  Known or secondary forms of hypertension.

          -  Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme
             (ACE) inhibitors.

          -  Hepatic or renal dysfunction. Creatinine > 150 umol or enzymes greater than 2 times
             upper limit of normal.

          -  Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitary
             kidney, post-renal transplant or with only one kidney.

          -  Uncorrected volume depletion.

          -  Biliary obstructive disorders.

          -  NYHA functional class congestive heart failure (CHF) III-IV.

          -  Coronary heart disease needing pharmacological therapy.

          -  Stroke within the preceding six months.

          -  Percutaneous transluminal coronary angioplasty (PTCA) within the preceding three
             months.

          -  History of angioedema.

          -  Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant
             cardiac arrhythmias as determined by the clinical investigator.

          -  Second or third degree AV block, left bundle branch block or any clinically relevant
             conduction abnormality as determined by the clinical investigator.

          -  Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
             stenosis of aortic or mitral valve.

          -  Administration of digoxin.

          -  Patients with a fasting glucose greater than 7.0

          -  History of drug or alcohol dependency.

          -  Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II
             antagonists, alpha-blockers, beta-blockers, calcium channel antagonists, direct
             vasodilators that cannot be stopped for the trial.

          -  Administration of other non-antihypertensive medications known to affect blood
             pressure (e.g. oral corticosteroids, monoamine oxidase [MAO] inhibitors, nitrates) at
             any time during the trial.

          -  Chronic use of salt substitutes containing potassium chloride; potassium supplements;
             extreme dietary restrictions.

          -  Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.

          -  Clinically significant hyperkalemia as defined by serum potassium level greater than
             5.2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less
             than 3.0 mEq/L.

          -  Patients receiving any investigational therapy within one month of signing the
             informed consent form.

          -  Known hypersensitivity to any component of telmisartan, ramipril or
             hydrochlorothiazide.

          -  Any other clinical condition which, in the opinion of the principal investigator,
             would not allow safe completion of the protocol and safe administration of trial
             medication.

          -  Blood donation in the preceding 1 month.